CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.
about
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cellsTumor-specific Th17-polarized cells eradicate large established melanomaTelomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II studyPhorbol myristate acetate and Bryostatin 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell lineUsing magnetic resonance imaging to evaluate dendritic cell-based vaccinationType I interferon is selectively required by dendritic cells for immune rejection of tumorsEnhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoproteinCD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsHuman papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.Natural immunity to pluripotency antigen OCT4 in humans.Tumour-infiltrating T-cell subpopulations in glioblastomas.MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients.The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.Generation of more effective cancer vaccinesPreventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response.Prostate-specific antigen vaccines for prostate cancer.The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells.HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer.CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.Regulatory T cells control the Th1 immune response in murine crescentic glomerulonephritisAdoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.CD4 cells can be more efficient at tumor rejection than CD8 cellsAntigenic targets for renal cell carcinoma immunotherapy.An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisitionTumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor TherapyPoint mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis.Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process.
P2860
Q24601213-48DB32BA-3F53-4590-A2B8-9A0D629116A0Q24648032-F135D679-6B5A-4CC4-991E-392738BF94C6Q24652592-17A2C8C7-8C99-40FD-977A-560704E34FB0Q24792961-F301A951-C5E5-42C9-807A-1305ACE39570Q27316977-B56E72D6-5CE7-4DB2-BF24-61099A77DAC7Q28248500-F8815379-1D67-4B0B-8C09-770E5856368CQ28383234-94A37E9F-023E-4EA7-92CC-E4D4C4B98E30Q30278537-EB6965F5-CA5B-43C8-8BCB-D2C36F22E12BQ30496580-81134803-E084-4B8D-96F4-BDF39DD3072AQ33584997-D8893708-7989-492C-9330-F7A7C8F57C16Q33730129-F1DD0357-569D-4506-80A2-E87D16779EC9Q33730171-7AD17BD1-1EBE-446F-A70E-779E4048843DQ33808144-21890AD4-76E1-4E95-A8CB-1F71B61573DCQ33928635-1F34666F-CF98-42B1-96F9-13E145925295Q33943553-55415C6C-FE30-4543-8527-0DD99B52CC5AQ34034978-D8E3661A-7478-4955-B250-FC9397604706Q34103645-94C67066-7533-4162-93D6-FEBF4C47E7F8Q34169981-38D557BB-1D4F-4EC5-9D1D-1DAFE4D75651Q34235915-5153D22D-EDF5-47FD-82D7-C9DEB464869AQ34243372-C2D49A91-7D6D-4E22-8F62-CA8C49F4CC0DQ34388367-7DEFAB55-889B-4692-A759-8A4D2173D877Q34418112-85E43223-097A-46DC-9F8B-DD0901512EE8Q34473746-6FA04533-0594-4CCB-A159-551CB26BD59EQ34602552-68364BAC-7D1A-4C8C-8D4E-77C403D70C74Q34982772-605257BF-33F4-47D9-98F9-026DE6ED5DF7Q34985471-A0E00137-AED2-4BDE-AAFF-82DAAA527552Q35065407-B5BD5B88-DCC7-4ADC-9216-718B24A04319Q35077753-FE07A0BB-3109-4825-BF36-56DA38B55559Q35628806-0B53404E-48C1-4708-8562-24445DA0B711Q35669339-9F2D1CFD-B5A0-479F-911F-88539EF6AB5FQ35828752-CF0E6CED-7344-4A2B-93B8-C9FFD552D70EQ35839925-AFC94364-0A03-4C69-B5AF-17510AAB9EF8Q35925619-8E5B51D0-A0C5-4D8D-9B09-F1F689214D2FQ35990678-613CF51B-97F2-4C91-9EDF-6F9700A0EB62Q36093442-D6965054-A132-41BD-BC3E-C2BC9D840E51Q36184954-991374A3-1493-4A73-BD09-909DA8808EFDQ36349514-95A6A139-829A-4FC9-8F82-57F7CEADA492Q36369462-1E825856-E53B-4079-A789-B03ADE997195Q36369709-B1EBD05C-9DB9-407A-8C85-764952BEAB8EQ36370554-7E7A924B-05A9-4E52-B54D-69D5EC1A18EA
P2860
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.
@ast
CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.
@en
type
label
CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.
@ast
CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.
@en
prefLabel
CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.
@ast
CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.
@en
P2093
P2860
P356
P1476
CD4(+) T cells eliminate MHC c ...... indirect effects of IFN-gamma.
@en
P2093
A Y Toledano
H Schreiber
P A Monach
R D Schreiber
S Wanderling
P2860
P304
P356
10.1073/PNAS.96.15.8633
P407
P577
1999-07-01T00:00:00Z